Search alternatives:
linear decrease » linear increase (Expand Search)
lower decrease » larger decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 2,181 - 2,200 results of 7,089 for search 'significantly ((((((lower decrease) OR (nn decrease))) OR (mean decrease))) OR (linear decrease))', query time: 0.50s Refine Results
  1. 2181
    Data Sheet 1_Exploring the glucose-lowering and anti-inflammatory immune mechanism of artemether by AMPK/mTOR pathway and microbiome based on multi-omics.docx

    Data Sheet 1_Exploring the glucose-lowering and anti-inflammatory immune mechanism of artemether by AMPK/mTOR pathway and microbiome based on multi-omics.docx by Tao Jiang (28401)

    Published 2025
    Save to List
    Saved in:
  2. 2182
    Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts.

    Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

    Published 2025
    Save to List
    Saved in:
  3. 2183
    Epac activation increased RLC phosphorylation via PLC/PKC.

    Epac activation increased RLC phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

    Published 2025
    Save to List
    Saved in:
  4. 2184
    SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort.

    SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Save to List
    Saved in:
  5. 2185
    KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort.

    KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Save to List
    Saved in:
  6. 2186
    Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts.

    Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

    Published 2025
    Save to List
    Saved in:
  7. 2187
    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  8. 2188
    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  9. 2189
    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  10. 2190
    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  11. 2191
    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  12. 2192
    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  13. 2193
    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  14. 2194
    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  15. 2195
    Joint Efficiency (%) of ABS Polymers at 800 rpm and 1200 rpm.

    Joint Efficiency (%) of ABS Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 2196
    Schematic of fixture.

    Schematic of fixture. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 2197
    Average shore hardness values of ABS and PC welded samples.

    Average shore hardness values of ABS and PC welded samples. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 2198
    Fabricated Fixture with labelled view.

    Fabricated Fixture with labelled view. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 2199
    Joint Efficiency (%) of PC Polymers at 800 rpm and 1200 rpm.

    Joint Efficiency (%) of PC Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 2200
    Tensile Strength (MPa) of PC Polymers at 800 rpm and 1200 rpm.

    Tensile Strength (MPa) of PC Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: